Non-perturbative imaging of intracellular drug exposure and drug response of kinase inhibitors

激酶抑制剂细胞内药物暴露和药物反应的非微扰成像

基本信息

  • 批准号:
    10391453
  • 负责人:
  • 金额:
    $ 38.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-08-01 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

Abstract: The past two decades have witnessed unparalleled success in the development of therapeutic kinase inhibitors targeting protein enzymes that are essential for cellular signaling cascades. The major challenges in kinase inhibitor drug treatment are interindividual variability, compromised drug efficacy, inevitable drug resistance, and toxicity. All of these properties depend strongly on intracellular drug concentration, which can be profoundly influenced by heterogeneous tissue penetration, drug transport, and lysosomal drug sequestration. However, currently there is no technology that can quantitatively examine intracellular concentration of kinase inhibitor drugs in living cells with subcellular spatial resolution. Stimulated Raman scattering (SRS) microscopy is an emerging chemical imaging technique that monitors molecule-specific vibrational signatures to provide quantitative, spatially resolved measurements of molecular concentration. We propose to develop novel SRS- based methods to enable non-perturbative, quantitative determination of single cell drug exposure for the first time. The first method uses the pH partition theory to derive cytosolic drug concentration based on lysosomal drug sequestration of weakly basic drugs. The second method uses an ultrasensitive Fourier-transform SRS technique and advanced chemometric analysis to directly determine cytosolic drug concentration. We will use these innovative methods to determine EGFR inhibitor penetration and drug sequestration in vitro using 3D tumor spheroids and in vivo using the dorsal skinfold chamber mouse model. In addition, we will systematically vary the physicochemical properties of drug compounds and determine their influence on drug transport, sequestration, and penetration. The second goal of this proposal is to elucidate the heterogeneity of cell response to kinase inhibitor drug treatment. Drug response of cancer cells depend on not only their genetic aberrations, but also their phenotypic states and microenvironments. Traditional proliferation assays measure the ensemble response of a cell population and are unable to resolve the highly heterogeneous drug response of cells in a 3D environment. We propose to develop a quantitative, high sensitivity single-cell growth-rate measurement technique based on deuterium pulse labeling. We will validate the use of growth rate change as an accurate predictor of drug response. By combining single cell drug exposure and drug response measurements in 3D tumor spheroids, we will further dissect the influence of drug penetration, intracellular drug exposure, and cell microenvironment on cell drug response. The proposed work builds on our strong expertise in label-free optical imaging and addresses key challenges in drug discovery and development by providing unprecedented measurement capabilities. The technologies and methods developed can be broadly applied to small molecule drugs, with great potentials to accelerate early stage drug discovery and empower personalized drug screening.
抽象的: 过去二十年见证了治疗性激酶抑制剂的开发取得了无与伦比的成功 靶向对细胞信号级联至关重要的蛋白质酶。激酶的主要挑战 抑制剂药物治疗存在个体差异、药物疗效受损、不可避免的耐药性和 毒性。所有这些特性都强烈依赖于细胞内药物浓度,这可以深刻地影响细胞内药物浓度。 受异质组织渗透、药物转运和溶酶体药物封存的影响。然而, 目前还没有技术可以定量检测细胞内激酶抑制剂的浓度 活细胞中的药物具有亚细胞空间分辨率。受激拉曼散射 (SRS) 显微镜是一种 新兴的化学成像技术,可监测分子特定的振动特征,以提供 分子浓度的定量、空间分辨测量。我们建议开发新颖的SRS- 基于方法首次实现单细胞药物暴露的非扰动定量测定 时间。第一种方法利用 pH 分配理论根据溶酶体浓度推导出胞浆药物浓度。 弱碱性药物的药物隔离。第二种方法使用超灵敏傅立叶变换 SRS 技术和先进的化学计量分析直接测定胞质药物浓度。我们将使用 这些创新方法使用 3D 确定 EGFR 抑制剂体外渗透和药物隔离 肿瘤球体和体内使用背侧皮褶室小鼠模型。此外,我们还将系统地 改变药物化合物的理化性质并确定它们对药物转运的影响, 隔离和渗透。该提案的第二个目标是阐明细胞反应的异质性 以激酶抑制剂药物治疗。癌细胞的药物反应不仅取决于它们的基因畸变, 还有它们的表型状态和微环境。传统的增殖测定测量整体 细胞群的反应,无法解析 3D 细胞的高度异质药物反应 环境。我们建议开发一种定量、高灵敏度的单细胞生长速率测量方法 基于氘脉冲标记的技术。我们将验证增长率变化的使用是否准确 药物反应的预测因子。通过在 3D 中结合单细胞药物暴露和药物反应测量 对于肿瘤球体,我们将进一步剖析药物渗透、细胞内药物暴露和细胞的影响 微环境对细胞药物反应的影响。拟议的工作建立在我们在无标签光学方面强大的专业知识之上 成像并通过提供前所未有的技术解决药物发现和开发中的关键挑战 测量能力。所开发的技术和方法可广泛应用于小分子 药物,具有加速早期药物发现和个性化药物筛选的巨大潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dan Fu其他文献

Dan Fu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dan Fu', 18)}}的其他基金

Fast volumetric imaging of oxygen delivery in the mouse brain at single red blood cell resolution
以单红细胞分辨率对小鼠大脑中的氧气输送进行快速体积成像
  • 批准号:
    10525881
  • 财政年份:
    2022
  • 资助金额:
    $ 38.5万
  • 项目类别:
Non-perturbative imaging of intracellular drug exposure and drug response of kinase inhibitors
激酶抑制剂细胞内药物暴露和药物反应的非微扰成像
  • 批准号:
    10606525
  • 财政年份:
    2019
  • 资助金额:
    $ 38.5万
  • 项目类别:
Non-perturbative imaging of intracellular drug exposure and drug response of kinase inhibitors - Admin Supp
激酶抑制剂细胞内药物暴露和药物反应的非微扰成像 - Admin Supp
  • 批准号:
    10392656
  • 财政年份:
    2019
  • 资助金额:
    $ 38.5万
  • 项目类别:
Non-perturbative imaging of intracellular drug exposure and drug response of kinase inhibitors
激酶抑制剂细胞内药物暴露和药物反应的非微扰成像
  • 批准号:
    9980422
  • 财政年份:
    2019
  • 资助金额:
    $ 38.5万
  • 项目类别:
Non-perturbative imaging of intracellular drug exposure and drug response of kinase inhibitors
激酶抑制剂细胞内药物暴露和药物反应的非微扰成像
  • 批准号:
    9796634
  • 财政年份:
    2019
  • 资助金额:
    $ 38.5万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 38.5万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 38.5万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了